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Background: Esophageal carcinoma is a significant worldwide 
health problem and the incidence is increasing faster than that of any 
other malignancy. 18F-2-deoxy-D-glucose (FDG)-positron emis-
sion tomography/computed tomography (PET/CT) is important in 
the management of patients with potentially resectable esophageal 
cancer and is useful in initial staging of locally advanced cancer and 
after neoadjuvant therapy. The purpose of this study is to determine 
the utility of FDG-PET/CT in the clinical staging of early-stage 
esophageal cancer. 
Methods: Subjects in this retrospective study were 79 consecu-
tive patients with cTisN0 (high-grade dysplasia) and cT1N0 pri-
mary esophageal adenocarcinoma diagnosed by endoscopy and 
endoscopic ultrasound biopsy that were evaluated with preop-
erative FDG-PET/CT and had not received neoadjuvant therapy. 
Seventh edition American Joint Committee on Cancer cTNM and 
FDG-PET/CT were compared with postoperative pTNM stag-
ing. pT1 was subdivided into intramucosal cancers with lamina 
propria or muscularis mucosa invasion (pT1a) and submucosal 
cancers (pT1b).
Results: In pT staging, the frequency of FDG uptake increased with 
increasing pT, from pT1a 21 of 39 (53.8%) to pT1b 19 of 22 (55.8%). 
pTis was three of five (60.0%). Similarly, the maximum standardized 
uptake value of FDG-avid lesions increased with increasing pT, with 
median values of 3.7 for pTis, 3.8 for pT1a and 4.2 for T1b. In cN 
staging, FDG-PET/CT was negative in 76 patients and positive in 
three patients. All three patients with FDG-avid nodes on FDG-PET/
CT were negative for metastatic disease on biopsy. In 12 patients with 
pN1 and in one patient with N2, FDG-PET/CT was falsely negative. 
Sensitivity and positive predictive value for pN disease were 0% and 
accuracy was 82%. There were no distant metastases. In cM staging, 
FDG-PET/CT was falsely positive in five patients (FDG avid nodules 
n = 3, distant nodal metastasis n = 2) and resulted in unwarranted 
biopsy in four patients.
Conclusion: FDG-PET/CT is not useful in the TNM staging of pri-
mary adenocarcinoma of the esophagus when endoscopy and biopsy 
indicate cTis and cT1. In fact, FDGPET/CT can be detrimental to 
patient management. Because regional nodal metastases are uncom-
mon and distant metastases rare, and as FDG-PET/CT can result in 
inappropriate clinical care, FDG-PET/CT should not be performed in 
the evaluation of early-stage esophageal cancer.
Key Words: Early esophageal adenocarcinoma, 18F-2-deoxy-D-
glucose FDG-PET/CT, Clinical Staging
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Esophageal carcinoma is a significant worldwide health problem and the incidence is increasing faster than that of 
any other malignancy.1 Accurate preoperative staging, includ-
ing the depth of tumor invasion, lymph node involvement, and 
the presence or absence of distant metastasis, is necessary to 
determine the appropriate treatment strategy and optimize 
patient outcomes. The pretreatment evaluation includes upper 
endoscopy and endoscopic ultrasound (EUS) for evaluation 
of the primary tumor and determination of locoregional nodal 
status. Computed tomography (CT) of the chest, abdomen, 
and pelvis is typically used for further delineation of local 
tumor extent and detection of nodal and distant metastases. 
Currently 18F-2-deoxy-D-glucose (FDG) positron emission 
tomography (PET)/CT is being used as a component of the 
initial routine evaluation of patients with esophageal cancer to 
detect the presence of metastases and predict response to treat-
ment.2–4 FDG-PET/CT improves the management of patients 
with advanced locoregional disease by detecting unsuspected 
metastases. However, in patients with an early T designation at 
diagnosis, there is little in the published literature demonstrat-
ing the utility of FDG-PET/CT in staging. In this study, we 
investigate the utility of FDG-PET/CT in the clinical staging 
of early-stage esophageal cancer.
Copyright © 2014 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/14/0908-1202
Clinical Staging of Patients with Early Esophageal 
Adenocarcinoma
Does FDG-PET/CT Have a Role?
Sonia L. Betancourt Cuellar, MD,* Brett W. Carter, MD,* Homer A. Macapinlac, MD,† Jaffer A. Ajani, MD,‡ 
Ritsuko Komaki, MD,§ James W. Welsh, MD,§ Jeffrey H. Lee, MD,║ Stephen G. Swisher, MD,¶  
Arlene M. Correa, PhD,# Jeremy J. Erasmus, MD,* and Wayne L. Hofstetter, MD**
*Diagnostic Radiology; †Nuclear Medicine; GI Medical Oncology; 
§Radiation Oncology Department; ║Gastroenterology Hepatitis and 
Nutrition; ¶Surgery; #Thoracic and Cardio Surgery-Research; and 
**Thoracic and Cardiovascular Surgery, The University of Texas MD 
Anderson Cancer Center, Houston, TX.
Disclosure: The authors declare no conflict of interest.
Jeremy J. Erasmus and Wayne L. Hofstetter contributed equally as senior 
authors.
Address for correspondence: Jeremy J. Erasmus, Department of Diagnostic 
Radiology, Unit 57, The University of Texas MD Anderson Cancer Center, 
1515 Holcombe Blvd., Houston, TX. E-mail: jerasmus@di.mdacc.tmc.edu
ORIGINAL ARTICLE
1203Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014 Clinical Staging of Patients with Early Esophageal Cancer
METHODS
Patient Selection
We retrospectively reviewed the medical records of 
patients with early-stage esophageal cancer treated at the 
University of Texas MD Anderson Cancer Center and iden-
tified sequential patients with high-grade dysplasia (cTisN0) 
and cT1N0 primary esophageal cancer diagnosed by endos-
copy and EUS biopsy from December 2001 to August 2011. 
There were 112 patients with high-grade dysplasia (cTisN0) 
and cT1N0 primary esophageal cancer. Eligibility criteria for 
this study included preoperative FDG-PET/CT performed at 
MD Anderson Cancer Center, EUS biopsy, adenocarcinoma 
histology, FDG-PET/CT within 90 days of resection and 
surgical resection without neoadjuvant therapy. Thirty-three 
patients were excluded because dedicated FDG-PET imag-
ing rather than the FDG-PET/CT was performed (n = 8). 
FDG-PET/CT was performed at other medical institutions 
and was unavailable for review (n = 8), and no FDG-PET/
CT was performed before resection (n = 1), squamous cell 
histology (n = 6), and where the EUS staging of the primary 
esophageal cancer did not clear specify the T1 designation 
as T1a or T1b (n = 3). Seven patients were excluded because 
FDG-PET/CT was performed more than 90 days before surgi-
cal resection. Seventy-nine patients met the inclusion criteria 
and formed the study group. After esophagectomy, clinical 
tumor, node, metastases (TNM) staging was compared with 
pathologic staging using the seventh edition American Joint 
Committee on Cancer (AJCC) staging system for esopha-
geal carcinoma. This study was approved by the University of 
Texas MD Anderson Institutional Review Board and was per-
formed in compliance with the Health Insurance Portability 
and Accountability Act.
FDG-PET/CT Technique
FDG-PET/CT in this study were collected from a sin-
gle institution from 2001 to 2011. FDG-PET/CT imaging 
was performed using one of four scanners (DST, 2 DRX, 
or DSTE- GE Healthcare, Milwaukee, WI). All patients had 
fasted for 6 hours before the FDG injection. A normal fast-
ing blood glucose level of less than 200 mg/dL was a standard 
requirement for imaging in all patients. PET data acquisition 
was performed in two-dimensional (2D) mode before January 
2008 and was changed to three-dimensional (3D) mode after 
that date. For 2D imaging, an intravenous injection of 555–
629 MBq (15–17 mCi) of FDG was administered in the arm 
or central venous catheter on the side opposite to the can-
cer, and emission scans were acquired at 3 minutes per field 
of view 70 ± 10 minutes after the FDG injection. The same 
procedure was used for 3D imaging except that the injected 
dose of FDG was 333–407 MBq (9–11 mCi). The acquired 
PET data were corrected for scatter coincidences, random 
coincidences, deadtime, and attenuation and reconstructed 
using OSEM on standard vendor-provided workstations. Non-
contrast-enhanced CT images, from the base of the skull to the 
mid-thigh, were acquired in helical mode (speed, 13.5 mm per 
rotation) during shallow breathing at a 3.75-mm slice thick-
ness, a tube voltage of 120 kVp, a tube current–time product 
of 150 mAs, and a 0.5-second rotation. Daily quality control 
procedures were performed on all PET scanners to ensure 
cross-calibration between systems and normalize differences 
in system performance. Maximum standardized uptake values 
(SUV
max
) were obtained using standard GE software. Regions 
of interest (ROI) were selected on the trans-axial images cor-
responding to foci of FDG uptake on the PET scan and abnor-
mal findings on the localization CT. The PET/CT studies were 
reviewed by one physician experienced in FDG-PET/CT inter-
pretation (J.J.E., 10 years’ experience) and blinded to clinical 
TNM and pathologic staging in the database. Discrepancies of 
the review and the database were reviewed by two physicians 
(J.J.E. and S.B.C.) and resolved by consensus.
Tumor Characteristics
 All patients had adenocarcinoma of the distal esopha-
gus and or gastroesophageal junction. pT1 was subdivided 
into intramucosal cancers with lamina propria or muscula-
ris mucosa invasion (pT1a) and submucosal cancers (pT1b). 
Pathologic tumor (pT) invasion after esophagectomy was Tis 
in five (6.3%), T1a in 39 (49.3%), T1b in 32 (40.5%), T2 in 
one (1.2%), and T3 in one (1.2%). In one patient (1.2%) with 
adenocarcinoma confirmed at EUS biopsy before resection, 
no malignancy was detected in the resected specimen most 
likely because of the small size/focus of malignancy. In 14 
patients, there were locoregional metastatic lymph nodes in 
the surgical specimens.
Data Analysis
 Association between SUV as a binary variable (<2.5 
versus ≥2.5) and pathological T stage (Tis, T1a, T1b, Tis) was 
examined using the Fisher’s exact test but no significant asso-
ciation was found (p = 0.933). Logistic regression using as 
outcome SUV greater than or equal to 2.5 and T1a as a refer-
ence group against T1b was also done, and again no significant 
association was found (p = 0.640). When considering those 
with SUV ≥2.5, we used the Kruskal-Wallis test and found no 
significant difference in the distribution of SUV among pT1a, 
pT1a, and pTis (p = 0.287).
We also performed a one-way ANOVA test for those 
with SUV greater than or equal to 2.5, and we did not find 
any significant association between SUV and pT1a, pT1b, and 
pTis (p = 0.357).
FDG-PET/CT Results
FDG-PET/CT was performed at a median of 37 days 
before surgical resection (range, 5–87 days). In 30 of 79 
(37.9%) FDG-PET/CT was done after the endoscopy (median 
10 days, range 2–47 days). In 46 of 79 (58.2%) the primary 
tumor was FDG-avid, whereas in 33 of 79 (41.8%) the tumor 
was not visible above regional background FDG uptake of 
the esophagus. The median SUV
max
 of the FDG-avid tumors 
was 4.0 (range, 2.5–19.0). The SUV
max
 of FDG-avid pri-
mary esophageal tumors increased with increasing pT, with 
a median of 3.7 for pTis, median of 3.8 for pT1a, and median 
of 4.2 for pT1b. However these values are not significant 
(p = 0.357). Differentiated by tumor depth, 3 of 5 (60%) pTis, 
21 of 39 (53.8) pT1a, and 19 of 23 (55.8%) pT1b tumors had 
increased FDG uptake, and again we were not able to prove 
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statistical significance (p = 0.933). Four tumors had a SUV
max
 
greater than 10 (T1a = 19, T1b = 15.7, 17.3, T2 = 13.2). 
Endoscopy and biopsy was performed before FDG-PET/CT 
in one of these patients. In the one patient with pT3 (tumor 
extending into the adventitia), the SUV
max
 was 3.3.
In cN designation, FDG-PET/CT was negative in 76 
patients and positive in three patients. All three patients 
with FDG-avid nodes on FDG-PET/CT were negative for 
malignancy on biopsy and pN0 was confirmed at resection. 
Endoscopy and biopsy was performed after FDG-PET/CT in 
these patients. Fourteen patients (pT1a [n = 3], pT1b [n = 9], 
pT2 [n = 1], and pT3 [n = 1]) had locoregional nodal metas-
tases in the resected specimens. In cN of these 14 patients, 
none of the lymph nodes were enlarged (>1 cm) on EUS or 
CT. FDG-PET/CT was falsely negative in the 13 patients who 
had pN1 and one patient who had pN2. Sensitivity and positive 
predictive value for pN disease was 0% and accuracy was 82%.
In cM designation, FDG-PET/CT was positive in five 
patients (FDG-avid lung nodules n = 3, distant nodal metas-
tasis n = 2). Biopsy of suspected distant metastasis performed 
in four of these patients was negative for malignancy and his-
tologic evaluation revealed inflammatory changes in all four 
patients. In the remaining patient, subsequent follow-up imag-
ing before treatment showed resolution of pulmonary nodules. 
In summary, there were no distant metastases, i.e., FDG-PET/
CT cM designation was falsely positive in five patients. No 
synchronous tumors were found.
DISCUSSION
The results from our study show that FDG-PET/CT is 
not useful in the TNM staging of primary adenocarcinoma 
of the esophagus when endoscopy and biopsy indicate cTis 
and cT1. In localized cancer, the depth of tumor invasion into 
the esophageal wall and adjacent tissues (T descriptor) and 
nodal involvement (N descriptor) are important in treatment 
planning.5–9 FDG-PET/CT has limited utility in determining 
the depth of tumor invasion. This limitation is greater with 
T1–T3 tumors, and while useful in detecting advanced tumor 
invasion into adjacent organs (T4), FDG-PET/CT has no role 
in the evaluation of superficial tumors.10 In a small study (19 
patients, 22 lesions) by Himeno et al.,11 all seven esophageal 
tumors confined to the mucosa (Tis or T1a) were negative on 
PET and not visualized on CT. In our study FDG uptake/SUV 
is positively, but poorly, correlated with pT. Five patients had 
pTis and three were FDG-avid (60%); 39 patients had pT1a 
tumors and 21 were FDG-avid (53.8%); and 32 patients had 
pT1b tumors and 19 were FDG-avid (55.8%). The reason for 
the variability in FDG uptake is likely because of tumors hav-
ing volumes below the resolution of PET/CT and differences 
in metabolic activity of the tumor cells. Another possibility 
is that increased uptake of FDG by activated macrophages as 
a result of inflammation induced by biopsy before PET/CT 
imaging could affect the SUV. In this regard, 30 (37.9%) of 
the patients had endoscopy and ultrasound biopsy performed 
before the FDG-PET/CT (median 10 days, range 2–47) and 
16 of these patients had focal increased FDG uptake within 
the esophagus. In two of the three pTis tumors that were FDG-
avid, the PET/CT was performed 2 and 9 days after the biopsy.
The designation of cT before therapy is not only 
important in the determination of management but also in 
the likelihood of having locoregional nodal metastases. In 
fact, there is a correlation between the depth of invasion and 
presence of nodal disease and as tumor depth increases, the 
likelihood of having nodal metastases increases.12 The mus-
cularis mucosa is an important boundary with tumors that 
invade through this layer associated with a higher incidence 
of lymph node metastases. The risk of nodal metastases has 
been reported as low as 0% in T1a disease and up to 46% in 
T1b patients.12 Conventional imaging is not optimal in iden-
tifying locoregional nodal metastatic disease and EUS is the 
modality of choice for assessing the depth of penetration of 
the primary tumor into the wall and the presence of locore-
gional nodal metastatic disease. In a recent meta-analysis 
that evaluated the value of FDG-PET/CT in the detection of 
regional nodal metastasis in patients with esophageal can-
cer before surgery, the pooled sensitivity and speciﬁcity for 
PET/CT were 0.62 (0.40–0.79) and 0.96 (0.93–0.98) per sta-
tion analysis and 0.55 (0.34–0.74) and 0.76 (0.66–0.83) per 
patient analysis.13 In our study the use of FDG-PET/CT was 
not useful in the detection of locoregional nodal metastasis. 
Three patients had false positive PET/CT studies for locore-
gional nodal metastatic disease and fourteen patients with 
locoregional nodal metastases at resection had false negative 
FDG-PET/CT studies (Fig. 1). Twelve of these patients had 
superficial primary esophageal malignancies (pT1a [n = 3), 
pT1b [n = 9]). In all the patients with locoregional nodal 
metastases, the metastases were microscopic and this likely 
accounts for the insensitivity of FDG-PET/CT in detecting 
pN disease in our study (sensitivity 0%, positive predictive 
value 0%, accuracy 82 %).
In patients with locoregionally advanced esophageal 
cancer, FDG-PET/CT is useful in the identification of distant 
metastasis, improving the accuracy of staging and preventing 
unnecessary surgery in patients with metastatic disease.2,10,14,15 
FDG-PET has been reported to have a pooled sensitivity of 
67% and pooled specificity of 97% to detect distant lymph 
node and organ metastases.16 Heeren et al.17 have reported 
that dedicated PET is useful in detecting distant metastasis in 
patients with locoregionally advanced (70% pT3/pT4) esoph-
ageal cancer. Using the sixth AJCC TNM staging, M1 upstag-
ing occurred in one of five patients compared with the use of 
CT and EUS alone, and there was also correct downstaging 
of 5% of the patients from M1 to M0.17 In a more recent pro-
spective study evaluating FDG-PET/CT in 491 patients with 
potentially resectable esophageal cancer, PET/CT led to clini-
cally important changes in stage. Seventy-four of 491 patients 
(15.1% or approximately one in every seven patients) were 
upstaged by PET/CT to M1 using the seventh AJCC TNM 
staging system.18 Our study shows that the likelihood of dis-
tant metastases in patients with superficial esophageal cancers 
is low. Specifically, none of the patients had distant metasta-
ses on conventional clinical staging and follow-up. Because 
the value of FDG-PET/CT in staging is higher in tumors with 
a high probability of distant metastatic disease, we believe 
FDG-PET/CT has no utility in the cM designation of patients 
with superficial esophageal cancers. In fact, FDG-PET/CT 
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was detrimental to patient management. In this regard, FDG-
PET/CT was falsely positive for distant metastases in five 
patients and resulted not only in unnecessary additional inva-
sive procedures but also delayed treatment in one of the five 
patients (Fig. 2).
The limitations of our study are those factors inherent in 
retrospective studies. In the period of the study (2001–2011) 
changes in PET/CT scanners and acquisition and reconstruc-
tion parameters occurred that potentially could have affected 
SUV quantification. In addition, variability in the time intervals 
between FDG-PET/CT and endoscopy, and FDG-PET/CT and 
resection are limitations. In this regard, in 30 (37.9%) of the 
patients FDG-PET/CT was done after the endoscopy and 16 of 
these patients had increased FDG uptake in the esophagus that 
potentially could have been as a result of the biopsy or could 
have resulted in an increase in the SUV of the primary tumor. 
However, our results regarding the drawbacks of FDG-PET/
CT in the staging of early esophageal cancers are in confor-
mity with an earlier study by Little et al., who concluded that 
FDG-PET/CT could not differentiate pTis from T1 and had 
poor sensitivity and positive predictive value for locoregional 
nodal metastasis. In addition, none of the 58 patients in their 
study had distant metastatic disease. Three patients (5.3%) had 
focal increased FDG uptake at distant sites and synchronous 
neoplasms were confirmed by biopsy.19 Although no synchro-
nous primary tumors were detected in our study, FDG uptake 
concerning for synchronous neoplasms has been reported to 
occur in approximately one in 10 patients, and of these only a 
minority will represent a malignant neoplasm that significantly 
impacts treatment.20 In addition, in a recent study that inves-
tigated the utility of FDG-PET/CT to diagnose synchronous 
neoplasms in patients with esophageal cancer, synchronous 
neoplasms were found in 34 of 200 patients (17%) and FDG-
PET/CT detected 20 of 37 sites (sensitivity 54.1%).21 Although 
the detection of a synchronous primary tumor is beneficial, the 
low incidence in patients with superficial esophageal cancer 
does not justify the cost of FDG-PET imaging.19,20
FIGURE 1.  (A) 78-year-old man 
with a distal T1a esophageal malig-
nancy. A, axial contrast-enhanced 
computed tomography shows an 
enlarged right paratracheal lymph 
node (arrow). (B) Coronal whole 
body maximal intensity projection 
image shows increased 18F-2-
deoxy-D-glucose (FDG) uptake in 
the superior mediastinum (arrow). 
Note the absence of increased FDG 
in the distal esophageal malignancy. 
(C) Axial fused positron emission 
tomography/computed tomography 
shows increased FDG uptake in the 
right paratracheal node suspicious 
for nodal metastasis. Transbronchial 
biopsy was negative for malignancy.
FIGURE 2.  65-year-old man with a distal T1a esophageal 
malignancy. Axial fused positron emission tomography/com-
puted tomography shows increased 18F-2-deoxy-D-glucose 
(FDG) uptake in a right lower lobe lung nodule suspicious for 
a metastasis. Note the absence of increased FDG in the distal 
esophageal malignancy (*). Transthoracic needle aspiration 
biopsy revealed marked acute inflammation and absence of 
malignancy.
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In summary, FDG-PET/CT is not useful in evaluation of 
adenocarcinoma of the esophagus when endoscopy and biopsy 
indicate cTis and cT1. FDG-PET/CT has no role in the evalua-
tion of the primary tumor, detection of locoregional nodal, and 
distant metastatic disease in these patients. Because regional 
nodal metastases are uncommon and distant metastases rare in 
patients with superficial esophageal tumors, and as FDG-PET/
CT can result in inappropriate patient management, FDG-
PET/CT should not be performed in the evaluation of patients 
with superficial esophageal cancers.
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